Semaglutide for PCOS: what the evidence actually supports

What did @branneisha actually say?

Honestly? Not much that's fact-checkable. The transcript is almost entirely garbled audio, likely music lyrics pulled from the video's background track rather than coherent speech. What we do have is the caption, which positions Ozempic (called "little miss zempy") as a last-resort solution for people who have "tried everything" for PCOS. That's the claim worth examining, because 477,000 views means a lot of people with PCOS are taking this framing seriously.

The caption reads: "If you feel like you're at the end of the road with finding things to work with your PCOS and you haven't heard or looked into little miss zempy... welcome to the right side of TikTok." That's a meaningful claim, even if it's wrapped in casual language. It positions semaglutide as a PCOS solution that people have been missing out on. Let's look at whether that's warranted.

Does the science back this up?

Partially, but the story is more complicated than a TikTok caption can convey. GLP-1 receptor agonists like semaglutide do appear to offer some real benefits for people with PCOS, particularly those dealing with insulin resistance and excess weight. But Ozempic is not approved by the FDA specifically for PCOS treatment, and the evidence base is still being built.

A 2023 systematic review by Jensterle et al. in Frontiers in Endocrinology found that GLP-1 receptor agonists reduced body weight, improved menstrual regularity, and lowered androgen levels in women with PCOS, though most studies were small and short-term. A 2022 randomized controlled trial by Cena et al. in Journal of Clinical Medicine showed liraglutide improved ovulatory function in PCOS patients with obesity. Semaglutide specifically has less PCOS-focused trial data, though larger trials are ongoing. The mechanism makes sense: PCOS is heavily tied to insulin resistance, and GLP-1 agonists improve insulin sensitivity directly.

What did they get wrong (or right)?

The framing that Ozempic is something PCOS patients haven't heard of is, at this point, pretty hard to justify. GLP-1 agonists have been discussed in PCOS communities for years, and any endocrinologist or reproductive endocrinologist worth seeing has this on their radar. The "you're on the right side of TikTok" framing implies discovery where there isn't really any.

What the video gets right, implicitly, is that PCOS treatment options have real gaps. Standard of care, typically metformin, lifestyle changes, and hormonal birth control, doesn't work well for everyone. That's a legitimate frustration. GLP-1 agonists are a reasonable next conversation to have with a doctor, particularly for patients with insulin-resistant PCOS and a BMI that qualifies them for coverage. But "end of the road" framing is medically irresponsible. There are fertility specialists, dietitians specializing in PCOS, inositol supplementation with actual trial support, and other options that don't require a GLP-1 prescription. Positioning one drug as the solution people have been missing minimizes all of that.

What should you actually know?

If you have PCOS and you're curious about GLP-1 medications, that's a reasonable conversation to bring to your doctor. But a few things matter here.

• Ozempic's approved indication is type 2 diabetes. Wegovy is approved for weight management. Neither is approved specifically for PCOS. Using them for PCOS is off-label prescribing, which is legal and common, but it means insurance coverage is often a fight.
• Not all PCOS is the same. Lean PCOS, PCOS without significant insulin resistance, may not respond the same way to GLP-1 agonists as the insulin-resistant phenotype. One drug does not fit all four PCOS subtypes.
• Side effects are real. Nausea, vomiting, gastroparesis risk with long-term use, and the still-debated question of muscle mass loss during rapid weight loss are all worth discussing with a provider.
• The research specifically on semaglutide for PCOS is thinner than social media suggests. Most of the GLP-1 and PCOS data comes from liraglutide trials. Extrapolating across the drug class is reasonable but not proven.

See a provider who specializes in PCOS, ideally a reproductive endocrinologist or an endocrinologist with PCOS experience, before starting any GLP-1 medication based on a TikTok caption.